Hoping to inform policymaking, vaccine access group unveils data platform


Coinciding with World Health Assembly discussions on vaccine strategy, The International Vaccine Access Center has released a data visualization platform--VIEW-hub--providing up-to-date info on the world’s vaccination coverage shortfalls.

The data show that even though vaccines against Hib, rotavirus and pneumococcal disease have been proven effective, the pathogens and associated conditions are still the world’s leading cause of death for children 5 and under. The team reports that 42% (56 million) of the world’s infants aren’t receiving a Hib vaccine, 60% (80 million) aren’t receiving a pneumococcal vaccine and 76% (102 million) aren’t receiving a rotavirus vaccine. IVAC says the tool can be used to determine coverage gaps and inform policy decisions.

IVAC found that 72% of the world's pneumonia and diarrhea child deaths occur in just 15 countries, with two very burdened countries--Nigeria and India--having recently introduced the jabs.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In one example, the IVAC says 44 African countries have introduced a pneumococcal vaccine, but only 17 have high or very high vaccination rates, suggesting a lack of effective policy among the others.

The data sources include the WHO, CDC, UNICEF, Gavi, Bill & Melinda Gates Foundation and vetted local government sources. Gavi and the Gates Foundation supported the project via grants.

- here's the release
- visit the VIEW-hub website

Related Articles:
MSF urges GSK, Pfizer to slash pneumococcal vaccine prices
Vaccines community aims for proactive approach to combat frequent, rapid outbreaks
Gates Foundation, WHO fund synthetic polio vaccine development

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.